Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
about
ABL tyrosine kinases: evolution of function, regulation, and specificityProtein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancerInhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemiaCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsThe Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiationThe effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell linesGlobal phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling.Generation of rac3 null mutant mice: role of Rac3 in Bcr/Abl-caused lymphoblastic leukemia.Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and BeyondPD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.Src kinase signaling in leukaemiaHematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells.BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemiaLyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line.Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesisSrc-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells.Targeting the leukemic stem cell: the Holy Grail of leukemia therapyAn inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cellsTargeted therapy of chronic myeloid leukemia.Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway.CD99 is a therapeutic target on disease stem cells in myeloid malignancies.NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migrationSrc family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
P2860
Q24299738-A6272119-68BC-4162-A11B-9DD2DE0F8D06Q24311296-01E8152B-C3A5-42C3-A7C6-B3F06CC5D6C0Q24803723-0F1D74FF-03A2-40CC-8630-8FF9C3E85D0EQ27004027-03CEA442-12F6-439B-A37D-7BA2491D82D3Q27025242-EF8AB89C-6784-41D0-BDF9-743062909DADQ27028181-D4911952-42A2-42DE-97B1-9D7CE8E20073Q30165112-B4770C7D-822F-4501-8727-3CC2E655C61EQ33369693-D6674922-1DBD-4E3F-BC7A-05AE4987F309Q33409151-829D2F65-6209-4DFB-847B-E2DF05C48054Q33753325-DF177ED3-60AF-439C-AA7E-EB4906FB68BEQ33863062-EA4BF1E1-9C54-4ED4-BB52-32847EE1D5BFQ33967180-FD4EED96-9FB6-4E53-8A74-1E7C76D7CE34Q33988398-8F79905C-E8CE-4824-A235-0DD9DE189F39Q34031967-1750D155-BE95-42F6-AB30-31487C0DC9B4Q34532048-4471A8CF-AF4E-4992-A674-70427FE90D4FQ34972855-967B9C14-A545-4AA1-B655-66C404C6ECC7Q35847727-E4E9AF07-F326-4325-9C90-B27B10E532DEQ35848373-5089845B-13C4-447A-9562-3CF3BD1AFDD8Q36116937-43976AD3-41C9-42BF-BD7E-3C815BD03DCDQ36140620-0D351DB5-59DE-45F6-B314-2C863F3F4FDAQ36371049-107E35C6-5ADC-4F16-98F0-AA8FBB19B546Q36478440-B111FE2A-7936-4F87-A758-0FF6E8710865Q36508969-F4C2DB8D-B99F-4203-9C48-7537FD43F24AQ37011134-02C91156-B3C8-4DF4-9E67-48B8DC90DC4EQ37043876-B84C076A-EDA2-4B0F-BE2E-45F09ED26E01Q37059746-E16CA330-B3D2-4D0A-BD0A-91700CE0E85AQ37171535-1C521941-7197-4B1D-8040-5F8278641E82Q37272565-855DFBD4-3C98-4749-A0B7-42BA80020B15Q37334825-2D34293D-C3C0-4FE4-B5FA-3AF378C67CC3Q37450433-A6A6A09F-897A-46B5-8A9E-6971C2665C6CQ37752572-DF2603B1-E3ED-4B0F-97A4-CF6B786437FBQ38923281-81CCA4E2-DD59-49DF-89F8-1B00658B86E5Q38998882-589782FB-C579-4B56-AB1F-9230A90ABE79Q39122858-7E7AD9E9-CA0D-4CD3-BD76-B9048E8A3E27Q41816292-3BA69CD3-81D6-4FE9-80BF-B6E8E60A5D9BQ41849009-1FFED75C-4CEA-43E8-A7D5-6738ABD42951Q41849340-114D66E5-25D3-43D2-BDA9-EBACE50BDBA2Q42017483-4DBE77AD-AEBA-4A42-926E-3F1710C5871CQ51747038-560B38DE-5ACA-41B8-92EC-E4B4A4079C78
P2860
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
@en
type
label
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
@en
prefLabel
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
@en
P2093
P1433
P1476
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
@en
P2093
Danhauser-Riedl S
Emmerich B
P304
P407
P577
1996-08-01T00:00:00Z